[Federal Register: March 19, 2003 (Volume 68, Number 53)]
[Notices]
[Page 13315-13316]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19mr03-95]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 98E-1217]
Determination of Regulatory Review Period for Purposes of Patent
Extension; TOPAMAX
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for TOPAMAX and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Commissioner of
Patents and Trademarks, Department of Commerce, for the extension of a
patent that claims that human drug product.
ADDRESSES: Submit written comments and petitions to the Dockets
Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to
http://www.fda.gov/dockets/ecomments.
http://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Claudia V. Grillo, Office of
Regulatory Policy (HFD-013), Food and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301-827-3460.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Director of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted, as well as any time that may have occurred before the
patent was issued), FDA's determination of the length of a regulatory
review period for a human drug product will include all of the testing
phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product TOPAMAX
(topiramate). TOPAMAX is indicated as adjunctive therapy in the
treatment of adults with partial onset seizures. Subsequent to this
approval, the Patent and Trademark Office received a patent term
restoration application for TOPAMAX (U.S. Patent No. 4,513,006) from
McNeilab, Inc., and the Patent and Trademark Office requested FDA's
assistance in determining this patent's eligibility for patent term
restoration. In a letter dated May 2, 2001, FDA advised the Patent and
Trademark Office that this human drug product had undergone a
regulatory review period and that the approval of TOPAMAX represented
the first permitted commercial marketing or use of the product.
Thereafter, the Patent and Trademark Office requested that FDA
determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
TOPAMAX is 3,844 days. Of this time, 2,984 days occurred during the
testing phase of the regulatory review period, while 860 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505 of the Federal Food,
Drug, and Cosmetic Act (the act) (21 U.S.C. 355) became effective: June
18, 1986. The applicant claims June 17, 1986, as the date the
investigational new drug application (IND) became effective. However,
FDA records indicate that the IND effective date was June 18, 1986,
which was 30 days after FDA receipt of the IND.
2. The date the application was initially submitted with respect to
the human drug product under section 505 of the act: August 18, 1994.
FDA has verified the applicant's claim that the new drug application
(NDA) for TOPAMAX (NDA 20-505) was initially submitted on August 18,
1994.
3. The date the application was approved: December 24, 1996. FDA
has verified the applicant's claim that NDA 20-505 was approved on
December 24, 1996.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 1,826 days of
patent term extension.
Anyone with knowledge that any of the dates as published is
incorrect may submit to the Dockets Management Branch (see ADDRESSES)
written or electronic comments and ask for a redetermination by May 19,
2003. Furthermore, any interested person may petition for a
determination regarding whether the applicant for extension acted with
due diligence during the regulatory review period by September 15,
2003. To meet its burden, the petition must contain sufficient facts to
merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d
sess., pp. 41-42, 1984.) Petitions should be in the format specified in
21 CFR 10.30.
Comments and petitions should be submitted to the Dockets
Management Branch (see ADDRESSES). Three copies of any information is
to be submitted, except that individuals may submit one copy. Comments
are to be identified with the docket number found in brackets in the
heading of this document. Comments and petitions may be seen in the
Dockets Management Branch between 9 a.m. and 4 p.m., Monday through
Friday.
[[Page 13316]]
Dated: February 5, 2003.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. 03-6507 Filed 3-18-03; 8:45 am]
BILLING CODE 4160-01-S